Abstract
Abstract Pancreatic cancer is one of the most aggressive human malignancies with a 5-year survival rate for all stages of only 6%. While surgery remains the most effective treatment for pancreatic cancer, the majority of patients that undergo resection go on to die of pancreatic cancer recurrence. The biology of pancreatic recurrence is poorly understood due to the lack of sufficient mouse models to study this aspect of the disease. Our laboratory has adapted the Syngraft mouse model in order to study metastatic recurrence of pancreatic cancer. The Syngraft model is an orthotopic syngeneic mouse model using a pancreatic tumor cell line derived from the genetically engineered model (KrasG12D/+; Ink4a flox/flox) that has been modified with lentiviral vectors expressing mCherry and luciferase. After orthotopic injection, tumor formation was detected with the IVIS Spectrum using injected luciferin. Mice underwent distal pancreatectomy with spleenectomy when the primary pancreatic tumor measured ∼107 photons/sec/cm2, with a mean time to surgical resection at 19 days. Mice were then followed for metastatic recurrence to the liver using the IVIS Spectrum, with a mean time to recurrence of 23 days. We were able to establish a rate of metastatic recurrence in the Syngraft mouse model of 41% to the liver. Research is ongoing to enhance the metastatic efficiency of the injected cell lines and to further characterize the model for evidence of single cell and micrometastases in the liver. This model holds potential to be a useful tool to study the cell and molecular biology of pancreatic cancer recurrence. Citation Format: Crissy Dudgeon, Ashley Tsang, Neil Campbell, Eric Collisson, Darren Carpizo. Adapting the Syngraft mouse model to study metastatic recurrence of pancreatic cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1441. doi:10.1158/1538-7445.AM2015-1441
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
